The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine

Vaccine

Volumn 31, Issue 22, 2013, Pages 2591-2597

  Fakharzadeh, Saideh ^a   Kalanaky, Somayeh ^a,d   Hafizi, Maryam ^a   Goya, Mohammad Mahdi ^e   Masoumi, Zahra ^a,c   Namaki, Said ^d   Shakeri, Nezhat ^a,d   Abbasi, Maryam ^a   Mahdavi, Mehdi ^a,b   Nazaran, Mohammad Hassan ^a,f  

^a Sodour Ahrar Shargh Company ^*  (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^f Owner of Nanochelating Technology   (Iran)

Author keywords

Adjuvant; Hep c; Nano chelator; Nano complex; Vaccine

Indexed keywords

GAMMA INTERFERON; HEP C NANO COMPLEX; HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; NANOSPHERE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ASSAY; CELLULAR IMMUNITY; CHELATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPLEEN CELL; TH1 CELL; TRANSMISSION ELECTRON MICROSCOPY;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; CYTOKINES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NANOPARTICLES;

EID: 84878355877     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.030     Document Type: Article

References (30)

1. Craven D.E., Awdeh Z.L., Kunches L.M., Yunis E.J., Dienstag J.L., Werner B.G., et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 1986, 105(September (3)):356-360.
2. Dienstag J.L., Werner B.G., Polk B.F., Snydman D.R., Craven D.E., Platt R., et al. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 1984, 101(July (1)):34-40.
3. Li Volti S., Caruso-Nicoletti M., Biazzo F., Sciacca A., Mandara G., Mancuso M., et al. Hyporesponsiveness to intradermal administration of hepatitis B vaccine in insulin dependent diabetes mellitus. Arch Dis Child 1998, 78(January (1)):54-57.
4. Kovacic V., Sain M., Vukman V. Efficient haemodialysis improves the response to hepatitis B virus vaccination. Intervirology 2002, 45(3):172-176.
5. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82(October (5)):488-496.
6. Livingston B.D., Alexander J., Crimi C., Oseroff C., Celis E., Daly K., et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 1999, 162(March (5)):3088-3095.
7. Jung M.C., Hartmann B., Gerlach J.T., Diepolder H., Gruber R., Schraut W., et al. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 1999, 261(September (2)):165-172.
8. Wintergerst E.S., Maggini S., Hornig D.H. Contribution of selected vitamins and trace elements to immune function. Ann Nutr Metab 2007, 51(4):301-323.
9. Lukac N., Massanyi P. Effects of trace elements on the immune system. Epidemiol Mikrobiol Imunol 2007, 56(February (1)):3-9.
10. Vogel J.U., Michaelis M., Neyts J., Blaheta R.A., Snoeck R., Andrei G., et al. Antiviral and immunomodulatory activity of the metal chelator ethylenediaminedisuccinic acid against cytomegalovirus in vitro and in vivo. Antiviral Res 2002, 55(July (1)):179-188.
11. Bagherpour B., Gharagozloo M., Moayedi B. The influence of iron loading and iron chelation on the proliferation and telomerase activity of human peripheral blood mononuclear cells. Iran J Immunol 2009, 6(March (1)):33-39.
12. Scholz M., Blaheta R.A., Markus B.H., Doerr H.W., Cinatl J. Immunomodulation and anticytomegalovirus activity of antioxidant metal chelators. Transplant Proc 1997, 29(February-March (1-2)):1272-1273.
13. Nanotechnology Park K. What it can do for drug delivery. J Control Release 2007, 120(July (1-2)):1-3.
14. Scholz M., Blaheta R.A., Henrich D., Cinatl J., Markus B.H., Doerr H.W., et al. Immunomodulatory properties of the metal chelators desferrioxamine and diethylenetriamine penta-acetic acid in vitro. Transplantation 1996, 62(November (9)):1371-1374.
15. Vingerhoets J., Vanham G., Kestens L., Penne G., Leroux-Roels G., Gigase P. Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production. Immunol Lett 1994, 39(February (2)):163-168.
16. Farrar M.A., Schreiber R.D. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993, 11:571-611.
17. Constant S.L., Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997, 15:297-322.
18. Borges O., Cordeiro-da-Silva A., Tavares J., Santarem N., de Sousa A., Borchard G., et al. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV 2008, 69(June (2)):405-416.
19. Diwan M., Tafaghodi M., Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release: Off J Control Release Soc 2002, 85(December (1-3)):247-262.
20. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002, 20(May (Suppl. 3)):S34-S39.
21. Roggendorf M., Schulte I., Xu Y., Lu M. Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck model. J Viral Hepat 2007, 14(November (Suppl. 1)):51-57.
22. Mondelli M.U., Varchetta S., Oliviero B. Natural killer cells in viral hepatitis: facts and controversies. Eur J Clin Invest 2010, 40(September (9)):851-863.
23. Bertoletti A., Maini M.K. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?. Curr Opin Microbiol 2000, 3(August (4)):387-392.
24. Fisicaro P., Valdatta C., Boni C., Massari M., Mori C., Zerbini A., et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009, 58(July (7)):974-982.
25. Isogawa M., Furuichi Y., Chisari F.V. Oscillating CD8(+) T cell effector functions after antigen recognition in the liver. Immunity 2005, 23(July (1)):53-63.
26. McClary H., Koch R., Chisari F.V., Guidotti L.G. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000, 74(March (5)):2255-2264.
27. Wieland S.F., Guidotti L.G., Chisari F.V. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000, 74(May (9)):4165-4173.
28. Suri D., Schilling R., Lopes A.R., Mullerova I., Colucci G., Williams R., et al. Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. J Hepatol 2001, 35(December (6)):790-797.
29. Takami Akagi M.B., Akashi M. Regulation of immune responses by nanoparticle-based vaccine: biodegradable nanoparticles as vaccine adjuvants and delivery systems. Adv Polym Sci 2012.
30. Jiang W., Gupta R.K., Deshpande M.C. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigen. Adv Drug Deliv Rev 2005, 57(3):391-410.